Humacyte (HUMA) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

HUMA Stock Forecast

Humacyte stock forecast is as follows: an average price target of $7.00 (represents a 59.82% upside from HUMA’s last price of $4.38) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.

HUMA Price Target

The average price target for Humacyte (HUMA) is $7.00 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $10.00 to $5.00. This represents a potential 59.82% upside from HUMA's last price of $4.38.

HUMA Analyst Ratings

Buy

According to 6 Wall Street analysts, Humacyte's rating consensus is 'Buy'. The analyst rating breakdown for HUMA stock is 0 'Strong Buy' (0.00%), 5 'Buy' (83.33%), 1 'Hold' (16.67%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Humacyte Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Oct 18, 2024	Matt O'Brien	Piper Sandler	$6.00	$4.86	23.46%	36.99%
Oct 18, 2024	Ryan Zimmerman	BTIG	$10.00	$4.86	105.76%	128.31%
Dec 20, 2022	Cowen Cowen	Cowen & Co.	$5.00	$2.21	126.50%	14.16%
May 15, 2022	Matt O'Brien	Piper Sandler	$4.00	$5.37	-25.51%	-8.68%

Row per page

Go to

The latest Humacyte stock forecast, released on Oct 18, 2024 by Matt O'Brien from Piper Sandler, set a price target of $6.00, which represents a 23.46% increase from the stock price at the time of the forecast ($4.86), and a 36.99% increase from HUMA last price ($4.38).

Humacyte Price Target by Period

	1M	3M	12M
# Anlaysts	-	2	2
Avg Price Target	-	$8.00	$8.00
Last Closing Price	$4.38	$4.38	$4.38
Upside/Downside	-100.00%	82.65%	82.65%

In the current month, the average price target of Humacyte stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Humacyte's last price of $4.38. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Nov 05, 2024	H.C. Wainwright	Buy	Buy	Hold
Oct 18, 2024	Cowen & Co.	Buy	Buy	Hold
Oct 18, 2024	Piper Sandler	Neutral	Neutral	Hold
Oct 18, 2024	BTIG	Buy	Buy	Hold
Sep 09, 2024	EF Hutton	-	Buy	Initialise
Sep 05, 2024	Benchmark	Buy	Buy	Hold
Aug 27, 2024	Cowen & Co.	Buy	Buy	Hold
Jun 17, 2024	Cowen & Co.	Buy	Buy	Hold
Aug 14, 2023	Piper Sandler	-	Neutral	Upgrade

Row per page

Go to

Humacyte's last stock rating was published by H.C. Wainwright on Nov 05, 2024. The company gave HUMA a "Buy" rating, the same as its previous rate.

Humacyte Financial Forecast

Humacyte Revenue Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Avg Forecast	$362.59M	$348.64M	$348.64M	$334.70M	$167.81M	$161.36M	$161.36M	$154.90M	$76.25M	$73.32M	$73.32M	$70.39M	$4.73M	$3.75M	$3.12M	$2.41M	$214.29K	$300.00K	$20.00K	$20.00K	$50.00K	$66.67K	$66.67K	$155.60K	$235.40K	$203.50K	$235.40K	$235.40K	$245.67K	$371.67K
High Forecast	$362.59M	$348.64M	$348.64M	$334.70M	$167.81M	$161.36M	$161.36M	$154.90M	$76.25M	$73.32M	$73.32M	$70.39M	$4.73M	$3.75M	$3.12M	$2.41M	$214.29K	$300.00K	$20.00K	$20.00K	$50.00K	$66.83K	$66.67K	$155.60K	$235.40K	$203.50K	$235.40K	$235.40K	$245.67K	$371.67K
Low Forecast	$362.59M	$348.64M	$348.64M	$334.70M	$167.81M	$161.36M	$161.36M	$154.90M	$76.25M	$73.32M	$73.32M	$70.39M	$4.73M	$3.75M	$3.12M	$2.41M	$214.28K	$300.00K	$20.00K	$20.00K	$50.00K	$66.50K	$66.67K	$155.60K	$235.40K	$203.50K	$235.40K	$235.40K	$245.67K	$371.67K
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	2	7	1	1	2	4	2	2	2	1	1	1	1	2	2
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Humacyte's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. HUMA's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Humacyte EBITDA Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	2	7	1	1	2	4	2	2	2	1	1	1	1	2	2
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-26.18M	$-24.62M	$-20.16M	$-8.32M	$-37.91M	$-20.58M	$-16.21M	$-19.69M	$-21.63M	$-30.35M
Avg Forecast	$-72.52M	$-69.73M	$-69.73M	$-66.94M	$-33.56M	$-32.27M	$-32.27M	$-30.98M	$-15.25M	$-14.66M	$-14.66M	$-14.08M	$-945.33K	$-750.55K	$-624.55K	$-482.54K	$-42.86K	$-60.00K	$-4.00K	$-4.00K	$-10.00K	$-13.33K	$-13.33K	$-31.12K	$-47.08K	$-122.10K	$-141.24K	$-22.17M	$-147.40K	$-16.67M
High Forecast	$-72.52M	$-69.73M	$-69.73M	$-66.94M	$-33.56M	$-32.27M	$-32.27M	$-30.98M	$-15.25M	$-14.66M	$-14.66M	$-14.08M	$-945.33K	$-750.55K	$-624.55K	$-482.54K	$-42.86K	$-60.00K	$-4.00K	$-4.00K	$-10.00K	$-13.30K	$-13.33K	$-31.12K	$-47.08K	$-122.10K	$-141.24K	$-17.73M	$-147.40K	$-13.34M
Low Forecast	$-72.52M	$-69.73M	$-69.73M	$-66.94M	$-33.56M	$-32.27M	$-32.27M	$-30.98M	$-15.25M	$-14.66M	$-14.66M	$-14.08M	$-945.33K	$-750.55K	$-624.55K	$-482.54K	$-42.86K	$-60.00K	$-4.00K	$-4.00K	$-10.00K	$-13.37K	$-13.33K	$-31.12K	$-47.08K	$-122.10K	$-141.24K	$-26.60M	$-147.40K	$-20.00M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2618.46%	1846.70%	1512.19%	267.39%	805.20%	168.52%	114.76%	0.89%	146.71%	1.82%

undefined analysts predict HUMA's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Humacyte's previous annual EBITDA (undefined) of $NaN.

Humacyte Net Income Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	2	7	1	1	2	4	2	2	2	1	1	1	1	2	2
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-25.11M	-	$-22.71M	$-61.84M	$13.57M	$-25.43M	$92.27M	$-16.47M	-	$-31.56M
Avg Forecast	$202.82M	$198.02M	$201.11M	$193.92M	$89.40M	$87.91M	$89.93M	$86.08M	$34.39M	$34.76M	$37.66M	$35.08M	$-27.06M	$-26.79M	$-26.00M	$-26.70M	$-30.02M	$-29.75M	$-28.47M	$-26.98M	$-28.67M	$-30.35M	$-26.26M	$-25.09M	$-28.04M	$-25.54M	$-25.96M	$-24.72M	$-24.37M	$-17.36M
High Forecast	$202.82M	$198.02M	$201.11M	$193.92M	$89.40M	$87.91M	$89.93M	$86.08M	$34.39M	$34.76M	$37.66M	$35.08M	$-27.06M	$-26.79M	$-26.00M	$-26.70M	$-27.52M	$-29.75M	$-28.47M	$-26.98M	$-27.52M	$-30.35M	$-26.26M	$-25.09M	$-28.04M	$-25.54M	$-25.96M	$-24.72M	$-24.37M	$-13.89M
Low Forecast	$202.82M	$198.02M	$201.11M	$193.92M	$89.40M	$87.91M	$89.93M	$86.08M	$34.39M	$34.76M	$37.66M	$35.08M	$-27.06M	$-26.79M	$-26.00M	$-26.70M	$-32.52M	$-29.75M	$-28.47M	$-26.98M	$-28.67M	$-30.35M	$-26.26M	$-25.09M	$-28.04M	$-25.54M	$-25.96M	$-24.72M	$-24.37M	$-20.83M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.88%	-	0.86%	2.46%	-0.48%	1.00%	-3.55%	0.67%	-	1.82%

Humacyte's average Quarter net income forecast for Mar 23 is $-25.09M, with a range of $-25.09M to $-25.09M. HUMA's average Quarter net income forecast represents a -284.83% decrease compared to the company's last Quarter net income of $13.57M (Dec 22).

Humacyte SG&A Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	2	7	1	1	2	4	2	2	2	1	1	1	1	2	2
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$6.00M	$6.07M	$3.08M	$5.23M	$5.83M	$6.19M	$5.18M	$5.68M	$15.73M	$5.40M
Avg Forecast	$3.12B	$3.00B	$3.00B	$2.88B	$1.44B	$1.39B	$1.39B	$1.33B	$656.38M	$631.14M	$631.14M	$605.89M	$40.69M	$32.30M	$26.88M	$20.77M	$1.84M	$2.58M	$172.16K	$172.16K	$430.39K	$573.86K	$573.86K	$1.34M	$2.03M	$1.75M	$2.03M	$2.03M	$2.11M	$3.20M
High Forecast	$3.12B	$3.00B	$3.00B	$2.88B	$1.44B	$1.39B	$1.39B	$1.33B	$656.38M	$631.14M	$631.14M	$605.89M	$40.69M	$32.30M	$26.88M	$20.77M	$1.84M	$2.58M	$172.16K	$172.16K	$430.39K	$575.29K	$573.86K	$1.34M	$2.03M	$1.75M	$2.03M	$2.03M	$2.11M	$3.20M
Low Forecast	$3.12B	$3.00B	$3.00B	$2.88B	$1.44B	$1.39B	$1.39B	$1.33B	$656.38M	$631.14M	$631.14M	$605.89M	$40.69M	$32.30M	$26.88M	$20.77M	$1.84M	$2.58M	$172.16K	$172.16K	$430.39K	$572.42K	$573.86K	$1.34M	$2.03M	$1.75M	$2.03M	$2.03M	$2.11M	$3.20M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	13.95%	10.58%	5.37%	3.91%	2.88%	3.53%	2.56%	2.80%	7.44%	1.69%

Humacyte's average Quarter SG&A projection for Mar 24 is $172.16K, based on 2 Wall Street analysts, with a range of $172.16K to $172.16K. The forecast indicates a -97.13% fall compared to HUMA last annual SG&A of $6.00M (Dec 23).

Humacyte EPS Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	2	7	1	1	2	4	2	2	2	1	1	1	1	2	2
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-0.24	-	$-0.22	$-0.60	$0.13	$-0.25	$0.90	$-0.16	-	$-0.72
Avg Forecast	$1.70	$1.66	$1.68	$1.62	$0.75	$0.74	$0.75	$0.72	$0.29	$0.29	$0.32	$0.29	$-0.23	$-0.22	$-0.22	$-0.22	$-0.25	$-0.25	$-0.24	$-0.23	$-0.24	$-0.25	$-0.22	$-0.21	$-0.23	$-0.21	$-0.22	$-0.21	$-0.20	$-0.20
High Forecast	$1.70	$1.66	$1.68	$1.62	$0.75	$0.74	$0.75	$0.72	$0.29	$0.29	$0.32	$0.29	$-0.23	$-0.22	$-0.22	$-0.22	$-0.23	$-0.25	$-0.24	$-0.23	$-0.23	$-0.25	$-0.22	$-0.21	$-0.23	$-0.21	$-0.22	$-0.21	$-0.20	$-0.20
Low Forecast	$1.70	$1.66	$1.68	$1.62	$0.75	$0.74	$0.75	$0.72	$0.29	$0.29	$0.32	$0.29	$-0.23	$-0.22	$-0.22	$-0.22	$-0.27	$-0.25	$-0.24	$-0.23	$-0.24	$-0.25	$-0.22	$-0.21	$-0.23	$-0.21	$-0.22	$-0.21	$-0.20	$-0.20
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.00%	-	1.00%	2.86%	-0.55%	1.17%	-4.13%	0.77%	-	3.51%

According to 2 Wall Street analysts, Humacyte's projected average Quarter EPS for Mar 23 is $-0.21, with a low estimate of $-0.21 and a high estimate of $-0.21. This represents a -261.63% decrease compared to HUMA previous annual EPS of $0.13 (Dec 22).

Humacyte Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
LRMR	Larimar Therapeutics	$6.13	$20.33	231.65%	Buy
GPCR	Structure Therapeutics	$30.10	$92.40	206.98%	Buy
LYRA	Lyra Therapeutics	$0.18	$0.50	177.78%	Hold
KURA	Kura Oncology	$10.06	$26.00	158.45%	Buy
KALV	KalVista Pharmaceuticals	$9.33	$22.67	142.98%	Buy
IMCR	Immunocore	$32.12	$70.75	120.27%	Buy
VRDN	Viridian Therapeutics	$19.62	$37.92	93.27%	Buy
CYTK	Cytokinetics	$47.67	$83.23	74.60%	Buy
HUMA	Humacyte	$4.38	$7.00	59.82%	Buy
NRIX	Nurix Therapeutics	$22.37	$32.20	43.94%	Buy
MIRM	Mirum Pharmaceuticals	$43.48	$57.25	31.67%	Buy
CRNX	Crinetics Pharmaceuticals	$57.03	$70.14	22.99%	Buy

HUMA Forecast FAQ

Is Humacyte a good buy?

Yes, according to 6 Wall Street analysts, Humacyte (HUMA) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 83.33% of HUMA's total ratings.

What is HUMA's price target?

Humacyte (HUMA) average price target is $7 with a range of $5 to $10, implying a 59.82% from its last price of $4.38. The data is based on 6 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Humacyte stock go up soon?

According to Wall Street analysts' prediction for HUMA stock, the company can go up by 59.82% (from the last price of $4.38 to the average price target of $7), up by 128.31% based on the highest stock price target, and up by 14.16% based on the lowest stock price target.

Can Humacyte stock reach $7?

HUMA's highest twelve months analyst stock price target of $10 supports the claim that Humacyte can reach $7 in the near future.

What are Humacyte's analysts' financial forecasts?

Humacyte's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $645.42M (high $645.42M, low $645.42M), average EBITDA is $-129M (high $-129M, low $-129M), average net income is $353.32M (high $353.32M, low $353.32M), average SG&A $5.56B (high $5.56B, low $5.56B), and average EPS is $2.96 (high $2.96, low $2.96). HUMA's analysts financial forecasts for the fiscal year (Dec 2028) are as follows: average revenue is $1.39B (high $1.39B, low $1.39B), average EBITDA is $-279M (high $-279M, low $-279M), average net income is $795.86M (high $795.86M, low $795.86M), average SG&A $12B (high $12B, low $12B), and average EPS is $6.66 (high $6.66, low $6.66).